Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 24;29(9):100640.
doi: 10.1016/j.jnha.2025.100640. Online ahead of print.

Baseline and longitudinal changes in peak expiratory flow rate as predictors of sarcopenia in older adults: A 4-year cohort study

Hui Qian  1 , Qifeng Chen  2 , Kangkang Chen  3
Affiliations

Baseline and longitudinal changes in peak expiratory flow rate as predictors of sarcopenia in older adults: A 4-year cohort study

Hui Qian et al. J Nutr Health Aging. .

Abstract

Objective: Peak expiratory flow rate (PEFR) is a cheap and simple tool for assessing airway patency and respiratory muscle strength. So far, the impact of PEFR, particularly its longitudinal changes, on the prevalence and incidence of sarcopenia remains underexplored. Therefore, we conducted a cross-sectional and longitudinal study to address this gap.

Methods: We analyzed data from the China Health and Retirement Longitudinal Study (CHARLS). A total of 5,280 older adults were selected as a cohort in 2011, of whom 3,686 were confirmed sarcopenia-free at baseline and followed through 2015. Longitudinal changes in PEFR were measured in 2011 and 2013, with complete paired data available for 2,904 subjects. Sarcopenia was diagnosed according to the 2019 Asian Working Group for Sarcopenia (AWGS). Multivariable logistic regression and discrete-time proportional hazards models were used to assess associations between baseline PEFR, 2-year PEFR changes, and sarcopenia risk, adjusting for potential confounders.

Results: A 1-standard deviation (SD) decrease in baseline PEFR was associated with 56% higher odds of prevalent sarcopenia (OR = 1.56, 95% CI = 1.38-1.75), and PEFR (% predicted) <80% with 93% higher odds (OR = 1.93, 95% CI = 1.49-2.50). Over the 4-year follow-up, these reductions were linked to increased risk of incident sarcopenia (HR = 1.26, 95% CI = 1.13-1.40, and HR = 1.47, 95% CI = 1.17-1.84, respectively). A decline from PEFR (% predicted) ≥80% to <80% was associated with 120% higher odds (OR = 2.20, 95% CI = 1.31-3.71), while improvement from <80% to ≥80% was linked to 30% lower odds (OR = 0.70, 95% CI = 0.50-0.96).

Conclusions: Lower baseline PEFR and its longitudinal decline were associated with increased risk of sarcopenia, while upward changes were linked to lower risk. These findings suggest that PEFR may serve as a practical early marker for identifying older adults at elevated risk of sarcopenia.

Keywords: CHARLS; Older adults; Peak expiratory flow rate; Sarcopenia.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no conflict of interests.

Figures

Fig. 1
Fig. 1
Flowchart of the sample selection process.
Fig. 2
Fig. 2
Number and percentage of the changes in PEFR (% predicted) classification (PEFR: peak expiratory flow rate).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyère O., Cederholm T., et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. doi: 10.1093/ageing/afy169. Epub 2018/10/13. PubMed PMID: 30312372; PubMed Central PMCID: PMCPMC6322506. - DOI - PMC - PubMed
    1. Chen L.K., Woo J., Assantachai P., Auyeung T.W., Chou M.Y., Iijima K., et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Directors Assoc. 2020;21(3):300–307.e2. doi: 10.1016/j.jamda.2019.12.012. Epub 2020/02/09. PubMed PMID: 32033882. - DOI - PubMed
    1. Petermann-Rocha F., Balntzi V., Gray S.R., Lara J., Ho F.K., Pell J.P., et al. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022;13(1):86–99. doi: 10.1002/jcsm.12783. Epub 2021/11/25. PubMed PMID: 34816624; PubMed Central PMCID: PMCPMC8818604. - DOI - PMC - PubMed
    1. Schaap L.A., van Schoor N.M., Lips P., Visser M. Associations of sarcopenia definitions, and their components, with the incidence of recurrent falling and fractures: the longitudinal aging study Amsterdam. J Gerontol A Biol Sci Med Sci. 2018;73(9):1199–1204. doi: 10.1093/gerona/glx245. Epub 2018/01/05. PubMed PMID: 29300839. - DOI - PubMed
    1. Malmstrom T.K., Miller D.K., Simonsick E.M., Ferrucci L., Morley J.E. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016;7(1):28–36. doi: 10.1002/jcsm.12048. Epub 2016/04/12. PubMed PMID: 27066316; PubMed Central PMCID: PMCPMC4799853. - DOI - PMC - PubMed

LinkOut - more resources